Biodexa Pharmaceuticals Plc (BDRX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Biodexa Pharmaceuticals Plc (BDRX) closed at USD 0.43 on 2026-10-15, a change of -98.5 % over the past year, with a market capitalization of USD 1.01M.

Biodexa Pharmaceuticals Plc recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Biodexa Pharmaceuticals Plc key figures

Previous close

USD 0.43 (2026-10-15)

1-year change

-98.5 %

Market cap

USD 1.01M

Enterprise value

USD -2.89M

P/E ratio (trailing)

0.01

P/E ratio (forward)

n/a

EPS (trailing)

63.74

EPS (forward)

0.00

PEG ratio

n/a

Price to book

0.03

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.00

Employees

11

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours; and MidaCore, a gold nanoparticle used for targeting sites of disease. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Biodexa Pharmaceuticals Plc and compare it with other stocks.